J Hand Surg Glob Online. 2024 Apr 14;6(4):500-503. doi: 10.1016/j.jhsg.2024.03.004. eCollection 2024 Jul.
ABSTRACT
PURPOSE: Trapeziometacarpal (TMC) joint prosthesis poses its own challenges for the treatment of TMC arthrosis, especially when compared with the present gold standard, arthroplasty. The aim of this study was to highlight possible outcome differences and patients’ satisfaction regarding the treatment of TMC arthrosis.
METHODS: We evaluated 100 patients with TMC arthrosis treated in two centers and divided into two groups: group A received TMC prosthesis (Touch), whereas group B was treated with arthroplasty, with a 2-year follow-up period.
RESULTS: In a comparative analysis, findings revealed group A’s superiority in the shortened disabilities of the arm, shoulder and hand questionnaire scores at 1 and 6 months, with significant differences: 34.6% vs 67.1% and 2% vs 9.1%, respectively (P < .0001). Although group A also showed lower the shortened disabilities of the arm, shoulder and hand questionnaire scores at 3 months, this was not statistically significant. Notably, at 1 and 2 years, group A demonstrated better scores without statistical significance. The Kapandji score differed significantly at 6 months: 9.8 vs 9.1 (P = .029). Although the visual analog scale showed generally lower values for the prosthesis group, no statistical differences emerged. Additionally, the M1/M2 ratio became significant postoperatively, favoring group A (P < .05).
CONCLUSIONS: Trapeziometacarpal prosthesis shows promise for TMC arthrosis, enhancing function, thumb length, and patient recovery, warranting further research and x-ray guidance.
TYPE OF STUDY/LEVEL OF EVIDENCE: Therapeutic III.
PMID:39166190 | PMC:PMC11331161 | DOI:10.1016/j.jhsg.2024.03.004
